HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M400304-JLR200v1 46/3/469    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Albert, T. S. E. Articles by Brown, B. G. Search for Related Content PubMed PubMed Citation Articles by Albert, T. S. E. Articles by Brown, B. G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 46, 469-474, March 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology

Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL

Timothy S. E. Albert^*, Philippe N. Duchateau, Samir S. Deeb^*,, Clive R. Pullinger, Min H. Cho, David C. Heilbron, Mary J. Malloy, John P. Kane and B. Greg Brown^1,*

^* Departments of Medicine, University of Washington, Seattle, WA
Genome Sciences, University of Washington, Seattle, WA
Cardiovascular Research Institute, University of California, San Francisco, CA

¹ To whom correspondence should be addressed. e-mail: bgbrown{at}u.washington.edu

Apolipoprotein L-I (apoL-I) is present on a subset of HDL particles and is positively correlated with plasma triglycerides (TGs). We measured plasma apoL-I levels in coronary artery disease (CAD) subjects with low HDL who were enrolled in an angiographic CAD prevention trial. At baseline, apoL-I levels (n = 136; range, 2.2–64.1 µg/ml) were right skewed with a large degree of variability. Multivariate analysis for biological determinants of apoL-I revealed that the log of VLDL-TG (+0.17; P < 0.05) and hyperglycemia (HG; +0.26; P < 0.005) independently predicted apoL-I level. Hyperglycemic patients (n = 24) had mean apoL-I levels >50% higher than normoglycemic subjects (n = 112; 13.2 vs. 8.3 µg/ml, respectively; P < 0.001). No relationship between apoL-I level and change in CAD was found (r = 0.06, P = 0.49). Simvastatin-niacin therapy did not alter apoL-I levels (n = 34; P = 0.27), whereas antioxidant vitamins alone increased apoL-I by >50% (n = 36; P < 0.01). Genotyping of a known apoL-I polymorphism (Lys166Glu) did not independently account for any of the variability in apoL-I levels.

In conclusion, we found TG and HG to be the strongest predictors of apoL-I within a dyslipidemic CAD population. These data provide further characterization of the novel HDL-associated apoL-I.

Supplementary key words diabetes mellitus • coronary artery disease • lipids • antioxidant vitamins • statins • niacin • high density lipoprotein

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?